Strategic Intelligence Report
Generated July 29, 2026
Artificial Intelligence
Earendil Labs
Strategic importance is our editorial rating of how central this entity is to the technology landscape we track; confidence reflects how well-sourced and current the underlying evidence is.
1
Chokepoint Score
1 other entity structurally depend on this one
Cooling
Activity
0 recorded changes in the last 90 days
Headquarters
Beijing, China / Delaware, USA
Website
Employees
200 (2026, approximate)
Founded
2022
Listing
private
Overview
A Delaware-incorporated, Beijing-headquartered biotech applying machine learning across the entire biologics R&D process, from antibody discovery through development and manufacturing. Earendil raised $787 million in March 2026, backed by Sanofi and the Pfizer/Hillhouse Biotech Development Fund alongside Dimension Capital, DST Global Partners, and Luminous Ventures; its AI-native platform has produced more than 40 programs including HXN-1001, a half-life extended anti-TL1A antibody ready for Phase 2 development, and it holds two major Sanofi licensing deals worth up to $1.72 billion and $2.56 billion in milestones for bispecific antibodies targeting autoimmune diseases.
Dependency Map
One hop in each direction — see Strategic Connections below for the full, sourced breakdown of every relationship.
Strategic Connections
Development
- AI Protein Design & Synthetic Biology: Earendil Labs develops an AI-native biologics discovery platform that has produced 40+ programs including a Phase 2-ready antibody.
Competition / Other
- Cradle: Earendil Labs competes with Cradle and other AI protein/biologics design companies for pharma partnerships and top computational biology talent.
- EvolutionaryScale: Earendil Labs competes with EvolutionaryScale and other AI protein design companies, though Earendil focuses on applied antibody/biologics programs versus EvolutionaryScale's foundation-model approach.
Strategic Risks
- No disclosed products have reached full regulatory approval despite substantial pharma licensing revenue
- Dual US/China corporate structure could face heightened scrutiny amid tightening biotech cross-border investment rules
Future Outlook
- Multiple IND filings planned for HXN-1001 and related programs in 2026-2027
- Continued expansion of pharma partnerships beyond its existing Sanofi relationships
Sources
- BioSpace / PR Newswire (Mar 2026) — Earendil Labs raises $787M for AI-driven biologics discovery and development
- PR Newswire (Jan 2026) — Earendil Labs' two Sanofi licensing deals worth up to $4.28B in combined milestones
Generated by InsightNodes — Technology Intelligence Platform. This report reflects sourced, evidence-backed information as of the dates cited above and is not investment advice.
Viewing the Full Analyst Report — switch to the Executive Summary.